Mucosal cytokine gene expression profiles as biomarkers of response to infliximab in ulcerative colitis

Abstract

High expression of Th1- and Th17-related cytokines in the mucosa of UC patients can potentially predict a favorable outcome of IFX induction therapy. Th2 and Treg-related mediators do not appear useful as predictive markers.

Infliximab Inhibits Activation and Effector Functions of Peripheral Blood T Cells in vitro from Patients with Clinically Active Ulcerative Colitis

“…4E). Addition of infliximab to cell cultures did not increase the level of soluble IL-2R (of which CD25 is a subunit) levels during the 7 days of cell culture (day 1; 34 (18-53) versus 22 (19)(20)(21)(22)(23)(24)(25)(26)(27)(28) + T were detectable at day one (Fig. 4 H).…”

Elevation of PRKCDBP, A Novel Transcriptional Target of TNF-α, and Its Downregulation by Infliximab in Patients with Ulcerative Colitis

“…In previous studies, mucosal TNF-a gene expression was identified as a marker of the response to therapy or long-term outcome and clinical relapse [17,28]. Other studies demonstrated that high pre-treatment mucosal interleukin-17A and interferon-c gene expression levels result in an increased likelihood of clinical and endoscopic remission after IFX therapy in patients with UC [29]. We observed that expression of PRKCDBP and TNF-a in colonic mucosa post-IFX treatment was significantly lower in endoscopic responders than in non-responders.…”

“…Because a subset of patients with UC clearly do not respond to IFX, it is important to identify predictors of a response to this rather expensive and potentially harmful drug to allow selection of appropriate patients [30,31]. However, few studies of the ability of mucosal biomarkers to predict the clinical course of IBD or the response to therapy are available [16,17,28,29,32]. Moreover, few validations have been performed, and mucosal biomarkers play a minor role, if any, in clinical practice.…”

Changes in cytokine profile may predict therapeutic efficacy of infliximab in patients with ulcerative colitis

“…4,5 It has also been assumed that alterations of the mucosal cytokine profile may be an important action of infliximab for UC. Rismo et al 8 reported that high expression of Th1-and Th17-related cytokines in the mucosa of UC patients were predictive of a favorable outcome of infliximab induction therapy. However, changes in various circulating cytokine profiles prior to and after infliximab treatment have not been extensively examined.…”